Market tracking data for Minerva Neurosciences (NASDAQ: NERV) indicates that short interest sits at approximately 2.45 million shares sold short, representing roughly 5.34 percent of the company's total public float. This level of short interest reflects ongoing caution among short sellers regarding clinical trial developments and regulatory milestones for its core pharmaceutical pipeline, resulting in moderate short-term volatility.